← back to search

Xavier Jaïs

Inserm · FR
Area of research
Pulmonary and Respiratory Medicine · Genetics
Research interest
Research interests include Pulmonary Hypertension Research and Treatments, Vascular Anomalies and Treatments, Cardiovascular Issues in Pregnancy, and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis.
h-index
85
citations
27,684
works
569
NIH funding
primary concept
email

Recent publications

Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension
Journal of the American College of Cardiology 2025cited by 18position: middledoi
Pulmonary arterial hypertension in adults with Still’s disease: another pulmonary manifestation associated with HLA-DRB1*15
Annals of the Rheumatic Diseases 2025cited by 8position: middledoi
Chronic thromboembolic pulmonary disease
European Respiratory Journal 2024cited by 94position: middledoi
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study
The Lancet Respiratory Medicine 2024cited by 33position: middledoi
Pulmonary vascular phenotype identified in patients with<i>GDF2</i>(<i>BMP9</i>) or<i>BMP10</i>variants: an international multicentre study
European Respiratory Journal 2024cited by 21position: middledoi
Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors
European Respiratory Journal 2024cited by 19position: middledoi
Outcomes and risk assessment in pulmonary veno-occlusive disease
ERJ Open Research 2024cited by 17position: middledoi
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management
The Lancet Respiratory Medicine 2023cited by 52position: middledoi
An emerging phenotype of pulmonary arterial hypertension patients carrying<i>SOX17</i>variants
European Respiratory Journal 2022cited by 42position: middledoi
COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study
American Journal of Respiratory and Critical Care Medicine 2022cited by 35position: middledoi
Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension
American Journal of Respiratory and Critical Care Medicine 2021cited by 194position: middledoi
External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry
European Respiratory Journal 2021cited by 192position: middledoi
Serum and pulmonary uric acid in pulmonary arterial hypertension
European Respiratory Journal 2021cited by 55position: middledoi
Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs
European Respiratory Journal 2021cited by 22position: middledoi
ERS statement on chronic thromboembolic pulmonary hypertension
European Respiratory Journal 2020cited by 525position: middledoi
Portopulmonary hypertension in the current era of pulmonary hypertension management
Journal of Hepatology 2020cited by 160position: middledoi
Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease
European Respiratory Journal 2019cited by 35position: middledoi
Chronic thromboembolic pulmonary hypertension
European Respiratory Journal 2018cited by 984position: middledoi
Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension
European Respiratory Journal 2018cited by 89position: middledoi
Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis
PLoS ONE 2018cited by 72position: middledoi
Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry
Respiration 2018cited by 34position: middledoi
Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension
European Respiratory Journal 2017cited by 694position: middledoi
RETRACTED: Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study
The Lancet Respiratory Medicine 2017cited by 263position: middledoi
Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension
Circulation 2017cited by 224position: middledoi
Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study
The Lancet Respiratory Medicine 2017cited by 177position: middledoi
Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension
European Respiratory Journal 2017cited by 151position: middledoi
Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension
Circulation 2016cited by 664position: middledoi
Pulmonary veno-occlusive disease
European Respiratory Journal 2016cited by 505position: middledoi
Initial dual oral combination therapy in pulmonary arterial hypertension
European Respiratory Journal 2016cited by 142position: middledoi
Resting pulmonary artery pressure of 21–24 mmHg predicts abnormal exercise haemodynamics
European Respiratory Journal 2016cited by 51position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Marc Humbert · Médecins Sans Frontières29 papers (2012–2025)Olivier Sitbon · Médecins Sans Frontières27 papers (2014–2025)David Montani · Médecins Sans Frontières25 papers (2014–2025)Laurent Savale · Centre d'Épidémiologie sur les Causes Médicales de Décès24 papers (2014–2025)Gérald Simonneau · Laboratoire d'Excellence en Recherche sur le Médicament et l'Innovation Thérapeutique22 papers (2014–2024)Vincent Cottin · Hôpital Avicenne13 papers (2014–2024) · 10 papers (2016–2024) · 10 papers (2017–2025) · 9 papers (2017–2024)Edmund Lau · The University of Sydney8 papers (2014–2017)Grégoire Prévôt · Université Claude Bernard Lyon 17 papers (2014–2021)Florence Parent · Inserm7 papers (2015–2019)Arnaud Bourdin · Conseil Régional du Languedoc-Roussillon6 papers (2014–2024)Jason Weatherald · Alberta Health Services6 papers (2017–2021) · 5 papers (2014–2017) · 5 papers (2015–2024)Pascal de Groote · Inserm5 papers (2014–2021)Élie Fadel · Université Paris-Saclay5 papers (2014–2022)François Picard · University of Miami4 papers (2014–2021) · 4 papers (2015–2017)